Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-101 in Acute Complicated Urinary Tract Infection
NCT06128213Phase 2Not yet recruiting
- Sponsor
- NRx Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 2 trial of d-cycloserine, lurasidone in complicated urinary tract infection (cUTI), pyelonephritis, sponsored by NRx Pharmaceuticals. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
d-cycloserinelurasidone
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on NCT06128213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128213.